Bernabeu-Wittel Máximo, Murcia-Zaragoza José, Hernández-Quiles Carlos, Escolano-Fernández Belén, Jarava-Rol Guadalupe, Oliver Miguel, Díez-Manglano Jesús, Ruiz-Cantero Alberto, Ollero-Baturone Manuel
Internal Medicine Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Internal Medicine Department, Hospital de la Vega Baja, Alicante, Spain.
J Pain Symptom Manage. 2014 Mar;47(3):551-65. doi: 10.1016/j.jpainsymman.2013.04.011. Epub 2013 Aug 30.
Efforts in developing useful tools to properly identify the end-of-life trajectory of patients with advanced medical diseases have been made, but the calibration and/or discriminative power of these tools has not been optimal.
Our objective was to develop a new, reliable prognostic tool to identify the probability of death within six months in patients with chronic medical diseases.
This was a multicenter, prospective, observational study in 41 Spanish hospitals, which included 1778 patients with one or more of the following: advanced conditions such as heart failure, respiratory failure, chronic renal failure, chronic liver disease, and/or chronic neurological disease. All patients were followed over six months. Each factor independently associated with death in the derivation cohort (884 patients from eastern areas of Spain) was assigned a prognostic weight, and the score was calculated by summing up the factors. The score's accuracy in the validation cohort (894 patients from western areas of Spain) was assessed by analyzing its calibration and discriminative power; we also calculated sensitivity, specificity, and positive and negative predictive values.
Mortality in the derivation/validation cohorts was 37.6%/37.7%, respectively. We identified six independent predictors of mortality (≥85 years, three points; New York Heart Association Class IV/Stage 4 dyspnea on the modified Medical Research Council, 3.5 points; anorexia, 3.5 points; presence of pressure ulcer(s), three points; Eastern Cooperative Oncology Group Performance Status of three or more, four points; and albuminemia ≤2.5g/dL, four points). Mortality in the derivation/validation cohorts according to risk group was 20%/21.5% for patients with zero points; 33%/30.5% for those with 3-3.5 points; 46.3%/43% for those with four to seven points; and 67%/61% for those who reached 7.5 or more points, respectively. The calibration was good (Hosmer-Lemeshow test, P=0.39), as was the discriminative power (area under the receiver operating characteristic curve of 0.69 [0.66-0.72]). The sensitivity (85%), specificity (86%), positive and negative predictive values (64% and 80%, respectively) at 180 days were high.
The PALIAR score is a precise and reliable tool for identifying the end-of-life trajectory in patients with advanced medical diseases.
人们已努力开发有用的工具来准确识别患有晚期疾病患者的临终轨迹,但这些工具的校准和/或鉴别力并不理想。
我们的目标是开发一种新的、可靠的预后工具,以识别患有慢性疾病的患者在六个月内死亡的概率。
这是一项在41家西班牙医院进行的多中心、前瞻性观察性研究,纳入了1778例患有以下一种或多种疾病的患者:心力衰竭、呼吸衰竭、慢性肾衰竭、慢性肝病和/或慢性神经疾病等晚期疾病。所有患者均随访六个月。在推导队列(来自西班牙东部地区的884例患者)中,每个与死亡独立相关的因素都被赋予一个预后权重,并通过对这些因素求和来计算得分。通过分析其校准和鉴别力来评估该得分在验证队列(来自西班牙西部地区的894例患者)中的准确性;我们还计算了敏感性、特异性以及阳性和阴性预测值。
推导队列/验证队列中的死亡率分别为37.6%/37.7%。我们确定了六个死亡率的独立预测因素(年龄≥85岁,3分;纽约心脏病协会IV级/改良医学研究委员会4级呼吸困难,3.5分;厌食,3.5分;存在压疮,3分;东部肿瘤协作组体能状态为3级或更高,4分;白蛋白血症≤2.5g/dL,4分)。根据风险组,得分为零的患者在推导队列/验证队列中的死亡率分别为20%/21.5%;得分为3 - 3.5分的患者为33%/30.5%;得分为4至7分的患者为46.3%/43%;得分达到7.5分或更高的患者为67%/61%。校准良好(Hosmer - Lemeshow检验,P = 0.39),鉴别力也良好(受试者工作特征曲线下面积为0.69[0.66 - 0.72])。180天时的敏感性(85%)、特异性(86%)、阳性和阴性预测值(分别为64%和80%)都很高。
PALIAR评分是一种用于识别患有晚期疾病患者临终轨迹的精确且可靠的工具。